We found that Flt3L injections dramatically increased F4/80-CD11c + DCs and CD103 + CD11c + DCs at the tumor site, and tumor-infiltrating DCs were further increased in the combination therapy group (Fig. 8d–f). This evidence concerns the gene FLT3LG and neoplasm.